



**HAL**  
open science

## More than smell. COVID-19 is associated with severe impairment of smell, taste, and chemesthesis

Valentina Parma, Kathrin Ohla, Maria G Veldhuizen, Masha Niv, Christine E. Kelly, Alyssa J Bakke, Keiland W Cooper, Cédric Bouysset, Nicola Pirastu, Michele Dibattista, et al.

### ► To cite this version:

Valentina Parma, Kathrin Ohla, Maria G Veldhuizen, Masha Niv, Christine E. Kelly, et al.. More than smell. COVID-19 is associated with severe impairment of smell, taste, and chemesthesis. *Chemical Senses*, 2020, 45 (7), pp.609-622. 10.1093/chemse/bjaa041 . hal-02911030

**HAL Id: hal-02911030**

**<https://hal.inrae.fr/hal-02911030>**

Submitted on 3 Aug 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/341260934>

# More than just smell – COVID-19 is associated with severe impairment of smell, taste, and chemesthesis

Preprint · May 2020

DOI: 10.1101/2020.05.04.20090902

CITATIONS

4

READS

1,530

122 authors, including:



**Valentina Parma**

Temple University

80 PUBLICATIONS 423 CITATIONS

SEE PROFILE



**Kathrin Ohla**

Forschungszentrum Jülich

53 PUBLICATIONS 818 CITATIONS

SEE PROFILE



**Masha Y Niv**

Hebrew University of Jerusalem

120 PUBLICATIONS 2,284 CITATIONS

SEE PROFILE



**Christine Kelly**

AbScent

6 PUBLICATIONS 95 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:



Genome-wide molecular landscapes of HPV-positive and HPV-negative head and neck squamous cell carcinoma [View project](#)



The role of visual and auditory deficits in human social relationships [View project](#)

## More than just smell - COVID-19 is associated with severe impairment of smell, taste, and chemesthesis

Valentina Parma<sup>1\*</sup>, Kathrin Ohla<sup>2\*</sup>, Maria G. Veldhuizen<sup>3\*</sup>, Masha Y. Niv<sup>4</sup>, Christine E. Kelly<sup>5</sup>, Alyssa J. Bakke<sup>6</sup>, Keiland W. Cooper<sup>7</sup>, Cédric Bouysset<sup>8</sup>, Nicola Pirastu<sup>9</sup>, Michele Dibattista<sup>10</sup>, Rishemjit Kaur<sup>11</sup>, Marco Tullio Liuzza<sup>12</sup>, Marta Y. Pepino<sup>13</sup>, Veronika Schöpf<sup>14</sup>, Veronica Pereda-Loth<sup>15</sup>, Shannon B. Olsson<sup>16</sup>, Richard C. Gerkin<sup>17</sup>, Paloma Rohlfs Domínguez<sup>18</sup>, Javier Albayay<sup>19</sup>, Michael C. Farruggia<sup>20</sup>, Surabhi Bhutani<sup>21</sup>, Alexander W. Fjaeldstad<sup>22</sup>, Ritesh Kumar<sup>23</sup>, Anna Menini<sup>24</sup>, Moustafa Bensafi<sup>25</sup>, Mari Sandell<sup>26</sup>, Iordanis Konstantinidis<sup>27</sup>, Antonella Di Pizio<sup>28</sup>, Federica Genovese<sup>29</sup>, Lina Öztürk<sup>3</sup>, Thierry Thomas-Danguin<sup>30</sup>, Johannes Frasnelli<sup>31</sup>, Sanne Boesveldt<sup>32</sup>, Özlem Saatci<sup>33</sup>, Luis R. Saraiva<sup>34</sup>, Cailu Lin<sup>29</sup>, Jérôme Golebiowski<sup>8</sup>, Liang-Dar Hwang<sup>35</sup>, Mehmet Hakan Ozdener<sup>29</sup>, Maria Dolors Guàrdia<sup>36</sup>, Christophe Laudamiel<sup>37</sup>, Marina Ritchie<sup>7</sup>, Jitka Trebická Fialová<sup>38</sup>, Jan Havlíček<sup>38</sup>, Denis Pierron<sup>39</sup>, Eugeni Roura<sup>35</sup>, Marta Navarro<sup>35</sup>, Alissa A. Nolden<sup>40</sup>, Juyun Lim<sup>41</sup>, Katie L. Whitcroft<sup>42</sup>, Lauren R. Colquitt<sup>29</sup>, Camille Ferdenzi<sup>25</sup>, Evelyn V. Brindha<sup>43</sup>, Aytug Altundag<sup>44</sup>, Alberto Macchi<sup>45</sup>, Alexia Nunez-Parra<sup>46</sup>, Zara M. Patel<sup>47</sup>, Sébastien Fiorucci<sup>8</sup>, Carl M. Philpott<sup>48</sup>, Barry C. Smith<sup>49</sup>, Johan N. Lundström<sup>50</sup>, Carla Mucignat<sup>19</sup>, Jane K. Parker<sup>51</sup>, Mirjam van den Brink<sup>52</sup>, Michael Schmuker<sup>23</sup>, Florian Ph.S Fischmeister<sup>53</sup>, Thomas Heinbockel<sup>54</sup>, Vonnie D.C. Shields<sup>55</sup>, Farhoud Faraji<sup>56</sup>, Enrique Santamaría<sup>57</sup>, William E.A. Fredborg<sup>58</sup>, Gabriella Morini<sup>59</sup>, Jonas K. Olofsson<sup>58</sup>, Maryam Jalessi<sup>60</sup>, Noam Karni<sup>61</sup>, Anna D'Errico<sup>62</sup>, Rafieh Alizadeh<sup>63</sup>, Robert Pellegrino<sup>64</sup>, Pablo Meyer<sup>65</sup>, Caroline Huart<sup>66</sup>, Ben Chen<sup>67</sup>, Graciela M. Soler<sup>68</sup>, Mohammed K.Alwashahi<sup>69</sup>, Antje Welge-Lüssen<sup>70</sup>, Jessica Freiherr<sup>71</sup>, Jasper H. B. de Groot<sup>72</sup>, Hadar Klein<sup>4</sup>, Masako Okamoto<sup>73</sup>, Olagunju Abdulrahman<sup>77</sup>, Pamela Dalton<sup>29</sup>, Carol H. Yan<sup>78</sup>, Vera V. Voznessenskaya<sup>79</sup>, Jingguo Chen<sup>80</sup>, Elizabeth A. Sell<sup>81</sup>, Julie Walsh-Messinger<sup>82</sup>, Nicholas S. Archer<sup>83</sup>, Sachiko Koyama<sup>84</sup>, Vincent Deary<sup>85</sup>, S. Craig Roberts<sup>86</sup>, Hüseyin Yanik<sup>3</sup>, Samet Albayrak<sup>87</sup>, Lenka Martinec Nováková<sup>88</sup>, Ilja Croijmans<sup>72</sup>, Patricia Portillo Mazal<sup>89</sup>, Shima T. Moein<sup>90</sup>, Eitan Margulis<sup>4</sup>, Coralie Mignot<sup>91</sup>, Sajidxa Marinn Iño<sup>92</sup>, Dejan Georgiev<sup>93</sup>, Pavan K. Kaushik<sup>94</sup>, Bettina Malnic<sup>95</sup>, Hong Wang<sup>29</sup>, Shima Seyed-Allaei<sup>90</sup>, Nur Yoluk<sup>3</sup>, Sara Razzaghi<sup>96</sup>, Jeb M. Justice<sup>76</sup>, Diego Restrepo<sup>97</sup>, GCCR<sup>74</sup>, Danielle R. Reed<sup>29</sup>, Thomas Hummel<sup>75</sup>, Steven D. Munger<sup>76</sup>, John E. Hayes<sup>6</sup>

\* denotes equal contribution

<sup>1</sup>Temple University, <sup>2</sup>Research Center Jülich, <sup>3</sup>Mersin University, <sup>4</sup>The Hebrew University of Jerusalem, <sup>5</sup>AbScent, <sup>6</sup>The Pennsylvania State University, <sup>7</sup>University of California Irvine, <sup>8</sup>Université Côte d'Azur, <sup>9</sup>The University of Edinburgh, <sup>10</sup>Università degli Studi di Bari A. Moro, <sup>11</sup>CSIR-Central Scientific Instruments Organisation, <sup>12</sup>“Magna Graecia” University of Catanzaro, <sup>13</sup>University of Illinois at Urbana Champaign, <sup>14</sup>Medical University of Vienna, <sup>15</sup>Université de Toulouse, <sup>16</sup>National Centre for Biological Sciences, Tata Institute of Fundamental Research, <sup>17</sup>Arizona State University, <sup>18</sup>University of Extremadura, <sup>19</sup>University of Padova, <sup>20</sup>Yale University School of Medicine, <sup>21</sup>San Diego State University, <sup>22</sup>Aarhus University, <sup>23</sup>University of Hertfordshire, <sup>24</sup>SISSA, International School for Advanced Studies, <sup>25</sup>Lyon Neuroscience Research Center, CNRS UMR5292 - INSERM U1028 - University Lyon 1, <sup>26</sup>University of Helsinki, University of Turku, <sup>27</sup>Aristotle University, <sup>28</sup>Leibniz-Institute for Food Systems Biology at the Technical University of Munich, <sup>29</sup>Monell Chemical Senses Center, <sup>30</sup>INRAE, <sup>31</sup>Université du Québec √† Trois-Rivières, <sup>32</sup>Wageningen University, <sup>33</sup>Medical Science University, <sup>34</sup>Sidra Medicine, <sup>35</sup>The University of Queensland, <sup>36</sup>IRTA, <sup>37</sup>DreamAir Llc, <sup>38</sup>Charles University, <sup>39</sup>Université de Toulouse-CNRS, <sup>40</sup>University of Massachusetts Amherst, <sup>41</sup>Oregon State University, <sup>42</sup>UCL, <sup>43</sup>Karunya University, <sup>44</sup>Biruni University, <sup>45</sup>Italian Academy Of Rhinology - assi sette laghi Varese, <sup>46</sup>Universidad de Chile, <sup>47</sup>Stanford University School of Medicine, <sup>48</sup>University of East Anglia, <sup>49</sup>University of London, <sup>50</sup>Karolinska Institutet, <sup>51</sup>University of Reading, <sup>52</sup>Maastricht University, <sup>53</sup>University of Graz, <sup>54</sup>Howard University College of Medicine, <sup>55</sup>Fisher College of Science and Mathematics, Towson University, <sup>56</sup>University of California San Diego Health, <sup>57</sup>Navarrabiomed-IDISNA, <sup>58</sup>Stockholm University, <sup>59</sup>University of Gastronomic Sciences, <sup>60</sup>The Five Senses Institute, Iran University of Medical Sciences, <sup>61</sup>Hadassah Medical Center, <sup>62</sup>Goethe Universit√st Frankfurt, <sup>63</sup>Iran University of Medical Sciences, <sup>64</sup>University of Tennessee, <sup>65</sup>IBM T.J. Watson Research Center, <sup>66</sup>Cliniques universitaires Saint-Luc, Brussels, Belgium, <sup>67</sup>Guangzhou Medical University, <sup>68</sup>Buenos Aires University and GEOG (Grupo de Estudio de Olfato y Gusto), <sup>69</sup>Sultan Qaboos University, <sup>70</sup>University Hospital Basel, Basel, <sup>71</sup>FAU Erlangen, <sup>72</sup>Utrecht University, <sup>73</sup>The University of Tokyo, <sup>74</sup>, <sup>75</sup>TU Dresden, <sup>76</sup>University of Florida, <sup>77</sup>The Federal University of Technology, Akure, Nigeria., <sup>78</sup>University of California San Diego, <sup>79</sup>Severtsov Institute of Ecology and Evolution RAS, <sup>80</sup>Second Affiliated Hospital of Xi'an Jiaotong University, <sup>81</sup>University of Pennsylvania, <sup>82</sup>University of Dayton, <sup>83</sup>The Commonwealth Scientific and Industrial Research Organisation (CSIRO), <sup>84</sup>Indiana University, <sup>85</sup>Northumbria University Newcastle, <sup>86</sup>University of Stirling, <sup>87</sup>Middle East Technical University, <sup>88</sup>Charles University, Faculty of Humanities, <sup>89</sup>Hospital Italiano de Buenos Aires, <sup>90</sup>Institute for Research in Fundamental Sciences, <sup>91</sup>Smell and Taste Center, Dresden, <sup>92</sup>Centro de Otorrinolaringología Respira Libre, <sup>93</sup>University Medical Centre Ljubljana, <sup>94</sup>Tata Institute of Fundamental Research, <sup>95</sup>University of São Paulo, Brazil, <sup>96</sup>Bilkent University, <sup>97</sup>University of Colorado Anschutz Medical Campus

## Author note

Correspondence concerning this article should be addressed to:

Dr. John E. Hayes  
Department of Food Science  
Pennsylvania State University  
220 Erickson Food Science Building  
University Park, PA 16802 USA  
Email: [jeh40@psu.edu](mailto:jeh40@psu.edu)  
Twitter: @TasteProf

**Keywords:** olfaction, gustation, coronavirus, hyposmia, ageusia, irritation

## Abstract

Recent anecdotal and scientific reports have provided evidence of a link between COVID-19 and chemosensory impairments such as anosmia. However, these reports have downplayed or failed to distinguish potential effects on taste, ignored chemesthesis, generally lacked quantitative measurements, and were mostly restricted to data from single countries. Here, we report the development, implementation and initial results of a multi-lingual, international questionnaire to assess self-reported quantity and quality of perception in three distinct chemosensory modalities (smell, taste, and chemesthesis) before and during COVID-19. In the first 11 days after questionnaire launch, 4039 participants (2913 women, 1118 men, 8 other, ages 19-79) reported a COVID-19 diagnosis either via laboratory tests or clinical assessment. Importantly, smell, taste and chemesthetic function were each significantly reduced compared to their status before the disease. Difference scores (maximum possible change  $\pm 100$ ) revealed a mean reduction of smell ( $-79.7 \pm 28.7$ , mean  $\pm$  SD), taste ( $-69.0 \pm 32.6$ ), and chemesthetic ( $-37.3 \pm 36.2$ ) function during COVID-19. Qualitative changes in olfactory ability (parosmia and phantosmia) were relatively rare and correlated with smell loss. Importantly, perceived nasal obstruction did not account for smell loss. Furthermore, chemosensory impairments were similar between participants in the laboratory test and clinical assessment groups. These results show that COVID-19-associated chemosensory impairment is not limited to smell, but also affects taste and chemesthesis. The multimodal impact of COVID-19 and lack of perceived nasal

obstruction suggest that SARS-CoV-2 infection may disrupt sensory-neural mechanisms.

## Introduction

In late 2019, a new virus, SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus strain 2), was reported in Wuhan, China (Zhu et al., 2020). The resulting COVID-19 disease has become a global pandemic with 3.18 million reported cases as of May 1, 2020 (World Health Organization, 2020). When assessing SARS-CoV-2 infection, clinicians initially focused on symptoms such as fever, body aches, and dry cough. However, emerging reports suggest sudden olfactory loss (anosmia or hyposmia) may be prevalent in patients with COVID-19 (Menni et al., 2020; Vetter et al., 2020). Olfactory disorders have long been associated with viral upper respiratory tract infections (URI) that cause the common cold and flu, including influenza and parainfluenza viruses, rhinoviruses, and other endemic coronaviruses (Soler et al., 2020). Taste disorders have been known to occur during and after respiratory viral infection, as well (Hummel et al., 2011). One case report found anosmia presenting with SARS (Hwang, 2006). Olfactory dysfunction due to viral infections may account for 11-45% of all olfactory disorders excluding presbyosmia (Nordin and Brömerson, 2008). The estimated prevalence of COVID-19-associated olfactory impairment may be higher than in COVID-19-independent postviral olfactory loss; estimations range from 5% to 85% in self-report studies, with differences noted between mild and severe cases (Bagheri et al., 2020; Gane et al., 2020; Giacomelli et al., 2020; Haldrup et al., 2020; Hopkins et al., 2020; Lechien et al., 2020a; 2020b; Mao et al., 2020; Menni et al., 2020; Yan et al., 2020a; 2020b). When psychophysical odor identification tests are used, this prevalence ranges from 76% in Europe using the Sniffin' Sticks (Lechien et al., 2020b)



to 98% in Iran using the UPSIT (Moein et al., 2020), though the severity of COVID-19 in these study cohorts may not be representative of the larger population. These anecdotes, pre-prints, letters, and peer-reviewed reports (for a review see, Pellegrino et al., in press), describe chemosensory disturbances in COVID-19 with characteristics that are similar to those seen in common URIs, such as isolated sudden onset of anosmia (Gane et al., 2020), occurrence of anosmia in mild or asymptomatic cases of COVID-19 (Hopkins et al., 2020), and loss of taste (Lechien et al., 2020a; Yan et al., 2020a). As of May 1, 2020, the European Centre for Disease Prevention and Control and the following countries or regions have listed smell loss as a symptom of COVID-19: Argentina, Chile, Denmark, Finland, France, Italy, Luxembourg, New Zealand, Singapore, South Africa, Slovenia, Switzerland, The Netherlands, and the United States of America (U.S.A.); many other countries or regions have not yet officially acknowledged smell loss as a symptom of COVID-19. To date, quantitative studies to determine the extent and detail of broad chemosensory changes in COVID-19 are lacking.

We use three separate sensory modalities – smell, taste and chemesthesis – to sense our chemical environment in daily life. The olfactory system (smell) detects volatile chemicals through olfactory sensory neurons in the nasal cavity. Odors in the external environment are sampled through the nostrils (orthonasal olfaction), while odors coming from food or drink in the mouth are sampled via the nasopharynx (retronasal olfaction). The gustatory system (taste) responds to non-volatile compounds in the mouth that elicit sensations of sweet, salty, bitter, sour and umami (savory). Finally,

chemesthesis detects other chemicals, often found in herbs or spices, that evoke sensations like burning, cooling or tingling.

While taste has occasionally been explored with respect to COVID-19 (Chen et al., 2020), chemesthesis remains unexamined in recent studies, despite anecdotal reports that it may be similarly compromised in persons with COVID-19. Smell, taste, and chemesthesis are often conflated, mostly because they produce a single experience of flavor during eating (Rozin, 1982; Spence et al., 2014; Duffy and Hayes, 2019; Hayes, 2019), and patients often report a loss of taste when in fact they are experiencing a loss of retronasal olfaction. Nevertheless, the olfactory and gustatory systems, along with parts of the somatosensory system that conveys chemesthesis, are separate sensory systems with distinct peripheral and central neural mechanisms (Shepherd, 2006; Green, 2012). To date, the impact of COVID-19 on each of these three chemosensory modalities remains poorly understood.

Chemosensory disturbances can result in quantitative reductions in smell or taste (i.e., anosmia/hyposmia and ageusia/hypogeusia, respectively), or as qualitative changes (e.g., distortions of smell and taste, termed parosmia and dysgeusia, or phantom sensations, termed phantosmia and phantogeusia). These key distinctions have been neglected in previous reports. Because these phenomena are not necessarily correlated and have different mechanisms (Holbrook et al., 2005; Iannilli et al., 2019; Reden et al., 2007), understanding how COVID-19 impacts chemosensation in both quantitative and qualitative ways should provide important insights into the mechanisms by which the SARS-CoV-2 virus affects the chemical senses.

Ideally, validated testing of chemosensory function would be combined with a review of a patient’s medical records, including laboratory test results (from viral swab or serology, “Lab Test”) to confirm the infectious agent. Due to limited laboratory test availability in many countries, the necessity in some medical settings for social distancing, and a potentially large number of asymptomatic or mild cases, it has been impractical or impossible to conduct such chemosensory testing for many individuals with COVID-19. Additionally, in many countries where testing resources are limited, laboratory testing has been limited to the most severe cases. Another diagnosis method is a clinical assessment by a medical professional (“Clinical Assessment”), either in-office or remotely via tele-medicine. Thus, the method of diagnosis – Lab Test versus Clinical Assessment – may be associated with differences in symptom severity, including severity of chemosensory impairments. To account for possible differences in the severity of infection as well as the availability of diagnosis options across countries, we collected information on diagnosis methods and compared chemosensory function between participants diagnosed with Lab Test vs. Clinical Assessment.

Given all the issues raised above, we deployed a crowd-sourced, multilingual, online study with a global reach (as of May 1, 2020 deployed in 27 languages); this survey has the potential to provide reproducible data from a large number of participants around the world. In this pre-registered report, we present data from 4039 participants who reported a COVID-19 diagnosis either via Lab Test or Clinical Assessment and who completed the questionnaire during the first 11 days the study was available online. Here we address two main research questions. First, we asked what chemosensory

changes are observed in participants with COVID-19, compared to before illness (i.e., within participants). Next, we asked whether the two diagnostic groups differ in chemosensory changes (i.e., between participants). For both diagnosis methods, we observed significant quantitative changes in smell, taste, and chemesthesis with COVID-19. Most chemosensory loss could not be accounted for by self-reported nasal obstruction, a factor commonly associated with diminished smell in other upper respiratory diseases (Doty, 2001). Further, we found little incidence of qualitative changes in olfactory function, with only a small percentage of participants reporting distorted smells (consistent with parosmia) or phantom smells (consistent with phantosmia). Together, these results provide an initial assessment of comprehensive chemosensory impairments associated with COVID-19.

## **Method**

### ***Preregistration***

We preregistered our hypotheses and analyses on April 19, 2020, at 12:20 AM Eastern Daylight Time (EDT), before the data became available (data reflected questionnaires submitted between April 7, 2020 6:00AM EDT and April 18, 2020 at 8:34 AM EDT) (Veldhuizen et al., 2020). We made periodic queries for counts of completed datasets before pre-registration until we reached the minimum number of participants according to the Sequential Bayes Factor Design (*section 2.3*). The data reported in this manuscript, along with analysis scripts, are available at OSF (<https://osf.io/a3vkw/>). The project is structured according to the research compendium created with the *rtools*

package (Marwick, 2019). The presented analyses are as pre-registered, unless specified otherwise.

### ***The GCCR core questionnaire***

The GCCR questionnaire, included in the list of research tools to assess COVID-19 by the NIH Office of Behavioral and Social Sciences Research (OBSSR) (Anonymous, 2020), measures self-reported smell, taste, and chemesthesis function as well as nasal blockage in participants with respiratory illness, including COVID-19, within the two weeks prior to completing the questionnaire. Relevant to the scope of the present manuscript, participants were asked to quantify their ability to smell, taste, and perceive cooling, tingling and burning sensations (chemesthesis) before and during the COVID-19, on separate, horizontally-presented, 100-point visual analogue scales (VAS). Participants were also asked to quantify their perceived nasal obstruction on a 100-point VAS with “not at all blocked” and “completely blocked” as anchors. This method captures the degree of change in the three chemosensory modalities in untrained participants; the within-subject design precludes a need for more sophisticated scaling methods (Kalva et al., 2014). Participants were also asked to report demographic information (i.e., year of birth, gender, and country of residence) as well as information related to their COVID-19 diagnosis and their respiratory illness-related symptoms, including smell and taste, in check-all-that-apply (CATA) format. We summarized the questions used in the present study in Figure 1. Please refer to the full questionnaire, included in the Supplementary materials, for question order and the labels on the anchors of each question.

Question	Response Options
I consent to participate.	[1]Yes [0]No
In which year (YYYY) were you born?	Numeric Entry
Which gender do you most identify with?	[0]Female [1]Male [2]Another not listed here [3]Prefer not to answer
Within the past two weeks, have you been diagnosed with or suspect that you have a respiratory illness?	[1]Yes [0]No
Have you been diagnosed with COVID-19?	[1]Yes-diagnosed based on symptoms only [2]Yes-diagnosed with viral swab [3]Yes-diagnosed with another lab test [4]No-I was not diagnosed, but I have symptoms [5]No-I had a negative test, but I have symptoms [6]No-I do not have any symptoms [7]Don't Know [8]Other
Rate your ability to smell before your recent respiratory illness or diagnosis	Line Scale <sup>a</sup>
Rate your ability to smell during your recent respiratory illness or diagnosis	Line Scale <sup>a</sup>
Have you experienced any of the following changes in smell with your recent respiratory illness or diagnosis? (Select all that apply)	[1]I cannot smell at all / Smells smell less strong than they did before [2]Smells smell different than they did before (the quality of smell has changed) [3]I can smell things that aren't there (e.g. I smell burning when nothing is on fire) [4]Sense of smell fluctuates (e.g. comes and goes)
How blocked was your nose before your recent respiratory illness or diagnosis?	Line Scale <sup>b</sup>
How blocked was your nose during your recent respiratory illness or diagnosis?	Line Scale <sup>b</sup>
Rate your ability to taste before your recent respiratory illness or diagnosis	Line Scale <sup>c</sup>
Rate your ability to taste during your recent respiratory illness or diagnosis	Line Scale <sup>c</sup>
Optional: Have you experienced changes to specific tastes with your recent respiratory illness or diagnosis? (Select all that apply)	[1]Sweet [2]Salty [3]Sour [4]Bitter [5]Savory/Umami
Rate your ability to feel these other sensations before your recent respiratory illness or diagnosis	Line Scale <sup>d</sup>
Rate your ability to feel these other sensations during your recent respiratory illness or diagnosis	Line Scale <sup>d</sup>

Figure 1. Portion of the questionnaire relevant to the scope of the present manuscript.

As of April 18th, 2020, the date on which the database was last queried for this report, the questionnaire was implemented in 10 languages: English, French, German,

Italian, Japanese, Kannada, Norwegian, Spanish, Swedish, and Turkish. Our translation protocol was modeled after the process developed by the Psychological Science Accelerator (Moshontz et al., 2018). Briefly, translations of the original English questionnaire involved three steps: i) the original (English) questionnaire was translated to the target language by independent translators, resulting in Translation Version A; ii) Version A was translated back from the target language to English by a separate group of independent translators, resulting in Version B; iii) Versions A and B were discussed among all translators, with the goal of resolving potential discrepancies between the two versions, resulting in the final Version C. All questionnaires in all languages were then implemented in Compusense Cloud, Academic Consortium (Guelph, Ontario), a secure cloud-based data collection platform with multilingual support.

### ***Study design***

This study compares quantitative changes (during vs. before the illness) in smell, taste, chemesthesis, and nasal obstruction as well as qualitative changes in smell and taste between two groups of respondents: those who reported a COVID-19 diagnosis as a result of an objective test such as a swab test (“Lab Test”) or those who reported a diagnosis from clinical observations by a medical professional (“Clinical Assessment”). Given the lack of effect size estimates in the literature, we employed a Sequential Bayes Factor Design (SBFD) that allows optional stopping with unlimited multiple testing (Schönbrodt et al., 2017). Specifically, we used a SBFD with a minimal number of participants and a temporal stopping rule to increase the probability of obtaining the desired level of evidence and to reduce the probability of obtaining misleading evidence.

The desired grade of relative evidence for the alternative vs. the null ( $BF_{10}$ ) hypothesis is set at  $BF_{10} > 10$  (strong evidence) for  $H_1$  and  $BF_{01} > 6$  (moderate evidence) for  $H_0$ . We derived the minimal  $N_{\min} = 480$  per group to start Sbfd through a Bayes Factor Design Analysis (BFDA) for fixed-n designs (Schönbrodt and Wagenmakers, 2018) for a two-independent-sample, two-sided testing, and a conservative Cohen's  $D = 0.2$  with 80% power of reaching a  $BF_{10} > 10$  and a  $BF_{01} > 6$  with a default prior. Our stopping rule follows a temporal criterion (data collection until April 18, 2020, 8:34 AM EDT) and  $N_{\min}$ . BF computation continues with every 20 participants added in the slowest accumulating group at a time until the thresholds of  $H_1$  or  $H_0$  are reached.

### ***Study setting***

Participation in this online study was voluntary and participants received no remuneration. Inclusion criteria were: consent to participate, age 19 years and older (based on birth year), and any form or suspicion of respiratory illness in the past two weeks. Participants were asked about their year of birth and the onset of their illness during the survey to confirm the inclusion criteria, and the survey terminated for non-eligible participants via branching logic. The nature of the questionnaire necessitated at least some secondary education in terms of language and distribution method (web survey) as well as internet access. The protocol complies with the revised Declaration of Helsinki and was approved as an exempt study by the Office of Research Protections at The Pennsylvania State University (Penn State) in the U.S.A. (STUDY00014904). The questionnaire was distributed globally in the different languages through traditional (i.e., print, television, radio) and social media (e.g., Twitter, Facebook), the website of the




Global Consortium for Chemosensory Research (GCCR; <https://gcchemosensr.org>), flyers, professional networks, and word of mouth. All data were collected via Compusense Cloud, which is compatible with use on a smartphone, tablet, laptop, or desktop computer. Data collection was compliant with privacy laws in the U.S.A. and the European Union (including California and General Data Protection regulation (GDPR) rules).

### ***Participants***

At the close of data collection on April 18, 2020, 4039 participants with a diagnosis of COVID-19 completed the ratings for smell, taste, chemesthesis ability, and nasal obstruction before and during their recent illness and were included in the present study. Participants who did not complete all ratings as mentioned above and/or gave inconsistent responses in three questions that addressed changes in smell perception (specifically, selecting changes in smell in “Have you had any of the following symptoms with your recent respiratory illness or diagnosis?”, reporting a difference in “Rate your ability to smell before your recent respiratory illness or diagnosis” and/or select at least one answer at the question “Have you experienced any of the following changes in smell with your recent respiratory illness diagnosis?”) or reported an age above 100 ( $n = 1$ ) were excluded from the sample. Of those included in the final sample, 2913 were women, and 1118 were men and 3 were other and 5 preferred not to say. Overall the age of the participants ranged from 19 to 79 years old (mean $\pm$ sd:  $41.38 \pm 12.20$  years old).

Here, we will compare respondents from two diagnostic groups: (a) participants who reported that their COVID-19 diagnosis was confirmed via objective Lab Test (N = 1402: 1064 F, 335 M; age mean $\pm$ sd: 40.73  $\pm$  12.29 years old) compared with (b) participants who reported that their COVID-19 diagnosis was obtained via clinical observation by a medical professional (N = 2637: 1849 F, 783 M; age mean $\pm$ sd: 41.72  $\pm$  12.14 years old). Based on self-report, respondents indicated they resided in the following countries: Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Costa Rica, Czech Republic, Denmark, Ecuador, Egypt, France, Germany, Greece, Iran, Ireland, Italy, Luxembourg, Morocco, Mexico, Netherlands, New Zealand, Norway, Paraguay, Portugal, Romania, Russia, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, Tunisia, Turkey, UK, United Arab Emirates, U.S.A. Figure 2 illustrates the derivation of the sample presented here.



*Figure 2.* Flow diagram showing the selection of individual observations included in the reported analysis. The number of observations remaining after each step of the evaluation process is indicated in each of the diagram boxes.

### ***Statistical analysis***

All analyses were performed in R (Team R Core Development, 2013) via RStudio. The scripts along with information on the computational environment and dependencies can be found at <https://osf.io/a3vkw/>. Information on the computational environment and dependencies used is also shared for future reproducibility. The code is also available on GitHub at <https://github.com/GCCR/GCCR001>, and includes a Jupyter notebook replicating the core analyses in Python.

To test our hypotheses ( $H_0$ : no difference between groups;  $H_1$ : difference between groups) in this between-participant SBFD, we conducted a Bayesian linear regression with the *lmBF* function from the *BayesFactor* package (Morey and Rouder, 2018) to detect changes (during minus before COVID-19) in smell, taste and chemesthetic abilities as well as nasal obstruction. Data report the Bayes factor and the proportional error estimate on the Bayes factor. We used the default Cauchy prior on the effect sizes under the  $H_1$  as the scale parameter spread which was set at its default value of  $r = \sqrt{2}/2$ . We performed robustness (sensitivity) checks by adjusting the Cauchy distribution to  $r = 0.5$  and  $r = 1$  to assess how the choice of prior affects the conclusions drawn from the analysis. We first assessed whether the model provides evidence in favor of  $H_1$  or  $H_0$ . To interpret the strength and the direction of those effects, we sampled from the models' posterior distributions (iterations = 1e4). Please refer to the pre-registration and the analysis script (see above) for further details. As reported in Table 1, the interpretation of the Bayes factors  $BF_{10}$  follows the classification scheme proposed by Lee and Wagenmakers (2013) and adjusted from (Jeffreys, 1961).

*Table 1. Interpretation of the Bayes factors  $BF_{10}$  follows the classification scheme proposed by Lee and Wagenmakers (2013) and adjusted from Jeffreys (1961).*

<b>Bayes Factor</b>	<b>Evidence Category</b>
>100	Extreme evidence for $H_1$
30 -100	Very strong evidence for $H_1$
10 -30	Strong evidence for $H_1$
3 - 10	Moderate evidence for $H_1$
1 - 3	Anecdotal evidence for $H_1$
1	No evidence
1/3 - 1	Anecdotal evidence for $H_0$
1/10 - 1/3	Moderate evidence for $H_0$
1/30 - 1/10	Strong evidence for $H_0$
1/100 - 1/30	Very strong evidence for $H_0$
< 1/100	Extreme evidence for $H_0$

### ***Exploratory non-preregistered analyses***

To quantify the association between the reports of (a) parosmia and phantosmia, (b) smell, (c) taste, (d) chemesthesis, and (e) a change in perceived nasal obstruction, we computed a correlation matrix that is visualized with *ggstatsplot* (Patil and Powell, 2018). To assess whether the proportion of parosmia and phantosmia reports differs between groups, we used a two-sample test for equality of proportions with a continuity correction. To characterize the relationship between perceived nasal blockage and chemosensory change, we used a principal component analysis (PCA) using *prcomp* from the R default *stats* package and we plotted the results with functions from the *FactoMineR* package (Lê et al., 2008). Additionally, to test whether different chemosensory function profiles exist in our sample, we performed a cluster analysis.

The best clustering scheme was with 3 clusters as determined with *NbCluster* (Charrad et al., 2014), which tests 30 methods that vary the combinations of number of clusters and distance measures for the k-means clustering. Cluster stability was estimated through a bootstrapping approach (100 iterations) with the *bootcluster* package (Yu, 2017).


## Results

### ***Degree of smell loss during COVID-19***

We observed a decrease in the ability to smell that was confirmed with extreme evidence (smell change against zero:  $BF_{10} = 4366.29 \pm 0\%$ ) and that was similar for both groups ( $BF_{10} = 2.17 \pm 0\%$  inconclusive evidence for a group difference, i.e.  $H_1$ ) (Figure 3A). The Clinical Assessment group exhibited a larger variance in the ability to smell during the illness as compared to the Lab Test group (Levene test,  $F_{(1,4037)} = 6.81$ ,  $p = 0.009$ ; see also the box plots in Figure 2A).

*Table 2. Mean and standard deviation (SD) for the ratings of smell, taste, chemesthesis, and nasal obstruction before and during COVID-19 in the Clinical Assessment and Lab Test groups.*

Variable	Clinical Assessment				Lab Test			
	Before COVID-19		During COVID-19		Before COVID-19		During COVID-19	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Smell	90.18	14.92	11.49	24.24	90.96	15.71	9.46	22.33
Taste	91.33	13.25	23.34	29.36	92.00	14.34	21.23	28.71
Chemesthesis	84.96	18.74	47.48	32.17	83.72	22.1	46.68	32.2
Nasal Obstruction	9.83	18.41	31.67	32.11	9.35	17.89	32.67	31.62



*Figure 3.* Raincloud plots representing ratings for smell (A), taste (B), and chemesthesis (C) before (left) and during (right) COVID-19. Within each subplot (from left to right), ratings from single participants are displayed as dots. Boxplots show the 1st to 3rd quartiles, the horizontal line denotes the median, and whiskers denote 1.5 times the interquartile range. The density distribution of the data shows the proportions of given ratings. COVID-19 diagnosis is coded such that Clinical Assessment is a lighter shade and Lab Test is a darker shade.



### Smell qualitative changes

Parosmia did not differ significantly between groups ( $X^2_{(1)} = 0.54, p = 0.463 [-0.01 - 0.03]$ ) and was reported by 7.77% (205 out of 2637) of participants in the Clinical Assessment and in 7.13% (100 out of 1402) the Lab Test group. Reports of phantosmia, however, did significantly differ between groups ( $X^2_{(1)} = 13.8, p < 0.001 [0.02 - 0.06]$ ): it was reported by 9.44% (249 out of 2637) of participants in the Clinical Assessment and in 6.28% (88 out of 1402) the Lab Test group. Reports of either parosmia or phantosmia negatively correlated with a report of a reduced ability to smell (on VAS) or a total smell loss (reported via CATA). Parosmia and phantosmia positively correlated with changes in smell, taste, and chemesthesis ratings but not with changes in perceived nasal obstruction (Figure 4).




Figure 4. Correlation matrices for individuals who reported parosmia (left, n = 296) and phantosmia (right, n = 324) across groups. The numbers refer to significant correlations at  $p < 0.001$  (Adjustment: Holm).

### ***Degree of taste loss in COVID-19***

Similar to what was seen with smell loss, we observed a reduced ability to taste that was confirmed with extreme evidence (taste change against zero:  $BF_{10}$  3424.52  $\pm$  0%) and that was similar for both groups ( $BF_{10}$  = 0.72  $\pm$  0% suggesting inconclusive evidence for a group difference). The Clinical Assessment group exhibited a larger variance in the ability to taste during COVID-19 as compared to the Lab Test group (Levene test:  $F_{(1,4037)} = 3.91$ ,  $p = 0.048$ ; see also the box plots in Figure 3B).

### ***Taste qualitative changes***

Participants were given the option to report changes in specific taste qualities (i.e., salty, sour, sweet, bitter or umami/savory) as a CATA question. Of all participants, 40% in both groups did not respond, 11% in both groups reported impairment of a single taste quality, and 48% reported impairment of two or more taste qualities (48% in the Clinical Assessment group, 49% in the Lab Test group). Salty taste change was most frequently reported: 46% in the Clinical Assessment group vs. 45% in the Lab Test group, and was significantly different between groups  $X^2_{(1)} = 4.37$ ,  $p = 0.037$  [0 – 0.07]. Umami (savory) taste change was less frequently reported (25%) in the Clinical Assessment group than in the Lab Test group (29%;  $X^2_{(1)} = 15.89$ ,  $p < 0.001$  [-0.11 – -0.04]). No significant differences in the frequency of reporting changes for sweet, bitter or sour taste was evident between groups (Table 3).

*Table 3. Frequency of responses, by group, for changes of specific taste qualities before and during COVID-19.*

Taste quality change	Clinical Assessment		Lab Test	
	Before COVID-19	During COVID-19	Before COVID-19	During COVID-19
Sweet	1477	1160	774	628
Salt	1426	1211	773	629
Bitter	1601	1036	852	550
Sour	1657	980	871	531
Umami	1969	668	991	411


### ***Degree of chemesthesis loss in COVID-19***

Similar to taste and smell, we observed a loss of chemesthetic ability that was confirmed with extreme evidence (chemesthetic change against zero:  $BF_{10}$  1459.98  $\pm$  0%) and that was similar for both groups ( $BF_{01}$  = 35.42  $\pm$  0% suggesting strong evidence against a group difference, Figure 3C). The distribution of chemesthetic ability showed a large 95%-CI [-2.82 – 1.88].

### ***Perceived nasal obstruction in COVID-19***

We observed a disease-related change in perceived nasal obstruction that was supported by extreme evidence (nasal obstruction change against zero:  $BF_{10}$  783.25  $\pm$  0%). No difference in the change in perceived nasal obstruction was found between groups as corroborated by moderate evidence against a group difference ( $BF_{01}$  = 14.52  $\pm$  0%; Figure 5A).

To further characterize potential relationships between changes in perceived nasal obstruction and reports of changes in the three chemosensory modalities, we computed a Principal Component Analysis (Figure 5B). Changes in smell, taste, and chemesthesis ratings (during minus before) correlated strongly with component 1 (smell:  $r = 0.72$ ; taste:  $r = 0.84$ ; chemesthesis:  $r = 0.74$ ), which explained 45.2% of the total multidimensional variance (inertia). In contrast, change in perceived nasal obstruction was strongly anti-correlated ( $r = -0.97$ ) with the orthogonal component 2, which explains 24.6% of the total inertia. These results indicate statistical independence of changes in chemosensory ability and perceived nasal obstruction. That is, changes in chemosensory ability and perceived nasal obstruction are statistically independent, so we conclude that changes in olfactory function in COVID-19 positive individuals cannot be attributed to nasal obstruction.




**Figure 5.** Nasal obstruction. A) The raincloud plot represents ratings for perceived nasal obstruction. From left to right, ratings from single participants are displayed as dots. Boxplots show the 1st to 3rd quartiles, the horizontal line denotes the median, and whiskers denote 1.5 times the interquartile range. The density distribution of the data shows the proportions of given ratings. COVID-19 diagnosis is color-coded, with Clinical Assessment in lighter shade and Lab Test in darker shade. B) Principal component analysis. Correlation circle of the perceptual changes with the 1st (abscissa) and 2nd (ordinate) principal components (PCs).

### **Chemosensory clustering**

Overall, distinct patterns of chemosensory dysfunction/distortion existed among the study participants. We used *k-means* algorithm to cluster respondents based on the similarities and differences in smell, taste, and chemesthesis change (Figure 6). The data-driven, 3-cluster solution (bootstrapped stability = 0.94) identified three groups that can be described by a combination of two chemosensory dimensions: i) the degree of smell and taste loss and ii) the degree of chemesthesis loss. Cluster 1 (N = 1767) is characterized by ratings reflecting substantial smell, taste and chemesthesis loss (centroids: smell: -88.89, taste: -86.74, chemesthesis: -72.39). Cluster 2 (N = 1724) is

characterized by ratings reflecting moderate smell/taste loss and unaffected chemesthesis (centroids: smell: -87.81, taste: -65.97, chemesthesis: -11.07). Cluster 3 (N = 548) is characterized by ratings reflecting substantial smell and taste loss, and preserved chemesthesis (centroids: smell: -24.33, taste: -20.97, chemesthesis: -6.87).



*Figure 6.* A) Correlations between the three principal components with respect to changes in three chemosensory modalities (i.e. taste, smell, and chemesthesis). Shades of gray indicate positive correlation, whereas shades of red indicate negative correlations. White denotes no correlation. B) Clusters of participants identified by *k-means* clustering. The scatterplot shows each participant's loading on dimension 1 (degree of chemesthesis loss, abscissa) and dimension 2 (degree of smell and taste loss, ordinate). Loadings for participants in cluster 1 (blue, N=1767) are characterized by significant smell and taste loss and preserved chemesthesis. Participants in cluster 2 (orange, N=1724) are characterized by ratings reflecting moderate smell/taste loss and preserved chemesthesis. Loadings for participants in cluster 3 (green, N=548) are characterized by significant smell, taste and chemesthesis loss.

## Discussion

Our study confirms and substantially extends previous reports showing that smell loss and taste loss are associated with COVID-19. Similar to other recent studies (Bagheri et al., 2020; Chen et al., 2020; Gane et al., 2020; Giacomelli et al., 2020; Haldrup et al., 2020; Hopkins et al., 2020; Lechien et al., 2020a, 2020b; Mao et al., 2020; Menni et al., 2020; Moein et al., 2020; Yan et al., 2020a, 2020b), we find that the majority of our participants with COVID-19 reports a severe reduction in the ability to smell as compared to before the onset of that disease. Notably, this smell loss was not associated with self-reported nasal obstruction, consistent with anecdotal reports. Further, we find that qualitative changes in smell (smell distortions or phantoms) were relatively rare. We found that taste, and to a lesser degree chemesthesis, were also significantly impaired for individuals with COVID-19. Together, these results suggest that COVID-19 broadly impacts chemosensory function across multiple sensory modalities, and that disruption of these may be a possible indicator of COVID-19.

This project is distinct from prior studies on the links between chemosensory dysfunction and COVID-19 in that it leverages a massive crowd-sourced, multinational approach to attack this urgent issue, and does so within a collaborative open science framework. This initial report is based on data in 10 languages from 41 countries; since the first tranche of data on April 18, 2020, 18 additional languages have been added on a rolling basis. The multinational, collaborative nature of the GCCR approach also sets it apart from other recently developed tools. Our hope is that an inclusive globally deployed assessment, coupled with publicly accessible data shared under contemporary

open science best practices, will serve as a foundation for future work. It is a limitation of this initial snapshot, however, that participants from different countries are not evenly represented. Cultural biases or country-specific manifestations of COVID-19 could potentially impact these results and will be explored by GCCR in future studies. Though our comprehensive self-report survey cannot replace in-person testing in a controlled clinical or laboratory setting, the gold standard for assessing alterations in chemosensory function, it efficiently and effectively addresses an emerging public health crisis with global scope of coverage. Thus, the model shown in this study of remote smell and taste assessment utilizing the internet may represent one way of reducing delays in assessment until aggressive physical distancing ends (Patel, 2020; Workman et al., 2020).

The mean change in ability to smell was substantial. Prior to onset of COVID-19, the mean rating for the ability to smell was over 90 on a 100-point VAS, yet during the disease, the mean rating dropped below 20. These data do not allow us to differentiate between individuals with partial (hyposmia) versus total loss (anosmia), and participants themselves may be unable to precisely characterize their degree of loss in the absence of objective olfactory testing (Hoffman et al., 2016; Loetsch and Hummel, 2006; Welge-Lüssen et al., 2005). Still, we can conservatively conclude that a major drop in the ability to smell is a hallmark of COVID-19. If the prevalence of COVID-19-associated smell loss is greater than that reported for the common cold or influenza (Beltrán-Corbellini et al., 2020), a different mechanism for disrupting olfactory function may be at play, or this



difference could also reflect increased tropism of SARS-CoV-2 for olfactory tissues (Baig et al., 2020).

Critically, the self-reported smell loss we observed is statistically independent of self-reported nasal obstruction. In common URIs, nasal obstruction can explain temporary smell impairments, a phenomenon many individuals have experienced in daily life. Here, estimates of nasal obstruction were based solely on self-report (we asked participants to rate the amount of “nasal blockage”); our data do not include objective, clinically validated measures of nasal breathing or obstruction. While nasal congestion does occur with COVID-19, it appears to be relatively rare in our sample. Still, the fact that many of our participants report substantial loss of olfactory function in the absence of concomitant nasal blockage seems remarkable.

In other instances of post-viral smell loss, about half of patients also experience a qualitative change in smell (Frasnelli et al., 2004; Reden et al., 2007; Rombaux et al., 2009). By contrast, less than 10% of participants reported parosmia or phantosmia symptoms. The rarity of qualitative changes in smell may be a hallmark of COVID-19 associated smell impairments. Alternatively, the present study may not have fully captured qualitative changes in smell, as they tend to emerge later in the course of other disorders (Bonfils et al., 2005) and the present assessment was limited to within at most two weeks of suspected illness or diagnosis. Further studies are needed to more comprehensively address this issue.

While taste loss has also been associated with COVID-19 in patient anecdotes and a few studies, in most cases it has not been clearly differentiated from changes in

smell. Here, we found that ratings of taste function were, like those for smell, substantially decreased in individuals with COVID-19. Participant ratings for taste function dropped from a mean of ~ 91 before COVID-19 onset to less than ~24 during the disease. It is well established that people often confuse changes in retronasal olfaction – an important component of flavor perception during eating and drinking – with a true taste loss. While we cannot rule this out completely given the study design, 60% of those reporting a taste loss also reported a decrease in their perception of at least one specific taste quality, with salty taste being the most common selection. These data support an interpretation that these participants were properly discerning taste from flavor. Compared to smell, the literature has described fewer examples of post-viral taste loss (Adour, 1994; Rubin and Daube, 1999). As the number of people responding to this questionnaire continues to grow on a rolling basis, the differences among different types of respiratory illnesses and their relationship to the degree of taste loss will be a major focus of forthcoming analyses.

Perhaps our most surprising finding was a notable loss of oral chemesthesis ability with COVID-19. Though the decrease is not as large as seen for smell and taste – an ~46% rating reduction for chemesthesis as compared to ~89% and ~76% percentage drop in smell and taste, respectively – it is significant. Interestingly, impairment of chemesthesis was typically accompanied by either taste and smell loss, while taste and smell loss could appear with normal chemesthesis. While nasal chemesthesis experienced with the inhalation of noxious chemicals like ammonia or ethanol is sometimes confused with smell, oral chemesthesis responses to compounds like

capsaicin from chili peppers or menthol from mint rarely is (Green, 1996). Though predominantly thought of as the chemical activation of trigeminal afferents carrying temperature, pain or vibration information from the oral, nasal and eye mucosa, other somatosensory nerves, including in the mouth, can also be affected (Green, 1996; McDonald et al., 2016). Chemesthesis (and taste) has been reported to accompany post-viral hyposmia resulting from a URI, at least in some cases (Ren et al., 2012; de Haro-Licer et al., 2013; Pellegrino et al., 2017; Fark and Hummel, 2013). Together with our findings for smell and taste, these data suggest that SARS-CoV-2 impacts all three major chemosensory modalities. The mechanisms are not clear and may be distinct for each chemosensory system. For example, transcriptomic studies of the olfactory mucosa of mouse and human suggests that sustentacular, Bowman's gland and stem cell populations, not olfactory sensory neurons themselves, contain ACE2, a receptor required for SARS-CoV-2 viral entry into cells. (Brann et al., 2020). The pattern of ACE2 expression indicates SARS-CoV-2 may infect tongue keratinocytes (Venkatakrisnan et al., 2020) but it is not clear if taste receptor cells or cranial nerves carrying taste or chemesthetic information can be infected by SARS-CoV-2. This virus could alternatively infect surrounding epithelia or blood vessels (Sungnak et al., 2020; Varga et al., 2020), or perhaps even target cells of the central nervous system (Baig et al., 2020).

Based on the stark changes in ratings reported here, one may speculate that both smell and taste loss in COVID-19 are all-or-none phenomena. Although, we cannot rule out that this is an artifact of scale usage, this explanation seems unlikely, as the distribution of the chemesthetic ability ratings is roughly rectangular: this suggests that

the all-or-none effect observed for smell cannot be simply attributed to participants using the scale in a discrete rather than continuous fashion. The self-reporting of olfactory function has been used in numerous studies; however, it is not unanimously accepted as it may suffer from low validity (Landis et al., 2003) due to under- and overreporting biases (Dalton and Hummel, 2000; Oleszkiewicz et al., 2020) and possible arbitrary usage. Here, we account for well-known individual differences in baseline chemosensory abilities, as well as use of rating scales, by using a within-subject design where participants rate their abilities for different time points (before and during COVID-19). We perform an analysis of differences between two assessments (e.g. during minus before COVID-19) rather than on absolute ratings. To better address the question of validity of change in ability ratings, future studies should compare these self-reported and recalled ratings to validated clinical tests before and during the individual's respiratory illness. However, in times of pandemic, the advantages of a remote assessment method may outweigh the potential decrease in validity compared to face-to-face clinical measures of taste and smell.

Lastly, we found that mean impairments of smell, taste, and or chemesthesis did not differ between study participants who reported a COVID-19 diagnosis based on a Lab Test and those who reported diagnosis based on a Clinical Assessment. However, the Clinical Assessment group exhibited a larger variance in chemosensory loss than the Lab Test group. This may reflect more variability in the accuracy of the diagnosis, as the Clinical Assessment group may include individuals who were misdiagnosed and may actually have another viral illness and/or who have a milder form of the disease.

## Conclusions

The GCCR consortium shows how health professionals, clinicians, patient advocates, and scientists can work together to undertake large-scale ground-breaking research of acute public health significance. The present research sets an example of how an emergent response to a global pandemic can be tackled with a crowd-sourced initiative that combines rigorous scientific standards with open-science practices. The established network, research infrastructure, protocol, and findings have the potential to influence current theories on the effects and mechanisms of COVID-19 on the chemical senses and to fuel future research in other areas.

## Acknowledgements

This work was supported financially with discretionary funds from the Pennsylvania State University (Penn State), including a gift from James and Helen Zallie given in support of Sensory Science at Penn State. The authors also wish to thank Jacqueline Dysart and Karen Phipps at Compusense and Olivia Christman at Penn State for all their help in rapidly deploying the GCCR survey in multiple languages. We are grateful to Marek Vondrak for their help with programming the automatization of the authorship list, Jae-Hee Hong for their editing contribution, and Tristram Wyatt for his role of facilitator of communication among the authors. Additionally, we would like to thank in their role as translators: Aditi Prasad, Alexandros Delides, Ali Khorram-Toosi, Aline Pichon, Amin Homayouni, Amol P Bhondekar, Angela Bassoli, Anshika Singh, Antti Knaapila, Arijit Majumdar, Bano Singh, Caterina Dinnella, Debarka Sengupta, Diana Wieck-Fjaeldstad, Dripta Roy, E. Bignon, Eman Hussien Ali Moussa Aboumoussa, Erminio Monteleone, Evangelia Tsakiropoulou, Francesca Boscolonata, Garnt Dijksterhuis, Gaurav Ahuja, Gauri Gharpure, Geetha GT, Giorgia Sollai, Hhardik Shah, Hinal Kharva, Hyoshin Kim, Ingrid Ekström, Ivan Mendez, Jakob Henriksen, Janina Seubert, Jens Sundbøll, Jian Zou, Jitendra Gosai, Kazushige Touhara, Kruttika Phalnikar, Lester Clowney, Lijo Kurian, Marcelo Antonio, Marina Litvak, Mohammad Yaqoob, Musa Ayman Nammari, N. Ravel, Nafiseh Alizadeh, Nasera Rizwana, Neva Bojovic, Nitindra Nath Bandyopadhyay, Orietta Calcinoni, Pavlos Maragoudakis, Pia Soee, Pooja Sarin, Poonam Adhikari, Prasad Kshirsagar, Pratheek HP, Rahul Kottath, Rashid Al Abri, Robert Greene, Rumi Iwasaki, Sanal Aman, Sangyeon Lim, Santosh Rajus, Sara Spinelli, Saurabh Mahajan, Seo Jin Cheong, Shima Taallohi, Simon Singh,

Soumya Palit, Sreejith Shankar, Srimanta Pakhira, Sudeshna Bagchi, Sudhir Verma, Takaki Miwa, Takushige Clowney, Tatiana Laktionova, Tatjana Abaffy, Vinaya Sahasrabuddhe, Vinod K Lokku, Xiaojing Cong, Yeonwoo Park, Yiqun Yu, Young Eun , Yuko Nakamura, Zaid Kamal Madni.

## References

Adour, K. K. (1994). Otological complications of herpes zoster. *Annals of Neurology*, 35(1 S), S62–S64. <https://doi.org/10.1002/ana.410350718>

Anonymous. (2020). COVID-19 OBSSR research tools. Retrieved on May 1, 2020 from [https://www.nlm.nih.gov/dr2/COVID-19\\_BSSR\\_Research\\_Tools.pdf](https://www.nlm.nih.gov/dr2/COVID-19_BSSR_Research_Tools.pdf)

Bagheri, S.H.R., Asghari, A.M., Farhadi, M., Shamshiri, A.R., Kabir, A., Kamrava, S.K., Jalessi, M., Mohebbi, A., Alizadeh, R., Honarmand, A.A., et al. 2020. Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak. *medRxiv*, 2020.03.23.20041889. <https://doi.org/10.1101/2020.03.23.20041889>

Baig, A.M., Khaleeq, A., Ali, U., and Syeda, H. 2020. Evidence of the covid-19 virus targeting the cns: Tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. *ACS Chemical Neuroscience*.

Beltrán-Corbellini, Á., Chico-García, J.L., Martínez-Poles, J., Rodríguez-Jorge, F., Natera-Villalba, E., Gómez-Corral, J., Gómez-López, A., Monreal, E., Parra-Díaz, P., Cortés-Cuevas, J.L., et al. 2020. Acute-onset smell and taste disorders in the context of covid-19: A pilot multicenter pcr-based case-control study. *European Journal of Neurology*.

Bonfils, P., Avan, P., Faulcon, P., and Malinvaud, D. 2005. Distorted odorant perception: Analysis of a series of 56 patients with parosmia. *Archives of Otolaryngology - Head and Neck Surgery*. 131:107–112. <https://doi.org/10.1001/archotol.131.2.107>

Brann, D.H., Tsukahara, T., Weinreb, C., Logan, D.W., and Datta, S.R. 2020. Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients. *bioRxiv*. 2020.03.25.009084. <https://doi.org/10.1101/2020.03.25.009084>

Charrad, M., Ghazzali, N., Boiteau, V., and Niknafs, A. 2014. NbClust: An rpackage for determining the relevant number of clusters in a data set. *Journal of Statistical Software*. 61:1–36. Retrieved from <http://www.jstatsoft.org/v61/i06/>

Chen, R., Wang, K., Yu, J., Chen, Z., Wen, C., and Xu, Z. 2020. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. *bioRxiv*. 2020.04.07.030650. <https://doi.org/10.1101/2020.04.07.030650>

Dalton, P., and Hummel, T. 2000. Chemosensory function and response in idiopathic environmental intolerance. *Occupational Medicine*. 15:539–556.

Doty, R.L. 2001. Olfaction. *Annual Review of Psychology*. 52:423–452.  
<https://doi.org/10.1146/annurev.psych.52.1.423>

Duffy, V.B., and Hayes, J.E. 2019. Biological Basis and Functional Assessment of Oral Sensation. In: H.L. Meiselman, ed. *Handbook of Eating and Drinking: Interdisciplinary Perspectives*. Cham: Springer International Publishing. pp. 1–25.  
[https://doi.org/10.1007/978-3-319-75388-1\\_22-1](https://doi.org/10.1007/978-3-319-75388-1_22-1)

Fark, T., and Hummel, T. 2013. Olfactory disorders: Distribution according to age and gender in 3,400 patients. *European Archives of Oto-Rhino-Laryngology*. 270:777–779.  
<https://doi.org/10.1007/s00405-012-2108-2>

Frasnelli, J., Landis, B., Heilmann, S., Hauswald, B., Hüttenbrink, K., Lacroix, J., Leopold, D., and Hummel, T. 2004. Clinical presentation of qualitative olfactory dysfunction. *European Archives of Oto-Rhino-Laryngology and Head & Neck*. 261:411–415.

Gane, S.B., Kelly, C., and Hopkins, C. 2020. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? *Rhinology*. <https://doi.org/10.4193/Rhin20.114>

Giacomelli, A., Pezzati, L., Conti, F., Bernacchia, D., Siano, M., Oreni, L., Rusconi, S., Gervasoni, C., Ridolfo, A.L., Rizzardini, G., et al. 2020. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*.  
<https://doi.org/10.1093/cid/ciaa330>

Green, B.G. 1996. Chemesthesis: Pungency as a component of flavor. *Trends in Food Science & Technology*. 7:415–420.

Green, B.G. 2012. Chemesthesis and the chemical senses as components of a "chemofensor complex". *Chemical Senses*. 37:201–206.  
<https://doi.org/10.1093/chemse/bjr119>



Haldrup, M., Johansen, M.I., and Fjaeldstad, A.W. 2020. Lugte- og smagstab som primære symptom på COVID-19. *Ugeskr Læger*. 3–5.

Haro-Licer, J. de, Roura-Moreno, J., Vizitiu, A., González-Fernández, A., and González-Ares, J.A. 2013. Long term serious olfactory loss in colds and/or flu. *Acta Otorrinolaringologica (English Edition)*. 64:331–338.

Hayes, J.E. 2019. Influence of Sensation and Liking on Eating and Drinking. In: H.L. Meiselman, ed. *Handbook of Eating and Drinking: Interdisciplinary Perspectives*. Cham: Springer International Publishing. pp. 1–25. [https://doi.org/10.1007/978-3-319-75388-1\\_21-1](https://doi.org/10.1007/978-3-319-75388-1_21-1)

Hoffman, H.J., Rawal, S., Li, C.-M., and Duffy, V.B. 2016. New chemosensory component in the us national health and nutrition examination survey (nhanes): First-year results for measured olfactory dysfunction. *Reviews in Endocrine and Metabolic Disorders*. 17:221–240.

Holbrook, E.H., Leopold, D.A., and Schwob, J.E. 2005. Abnormalities of axon growth in human olfactory mucosa. *The Laryngoscope*. 115:2144–2154.

Hopkins, C., Surda, P., and Kumar, N. 2020. Presentation of new onset anosmia during the COVID-19 pandemic. *Rhinology*. <https://doi.org/10.4193/Rhin20.116>

Hummel, T., Landis, B.N., and Hüttenbrink, K.-B. 2011. Smell and taste disorders. *GMS Curr Top Otorhinolaryngol Head Neck Surg*. 10. <https://doi.org/10.3205/cto000077>

Hwang, C.S. 2006. Olfactory neuropathy in severe acute respiratory syndrome: Report of a case. *Acta Neurologica Taiwanica*. 15:26–28.

Iannilli, E., Leopold, D.A., Hornung, D.E., and Hummel, T. 2019. Advances in Understanding Parosmia: An fMRI Study. *Orl*. 81:185–192. <https://doi.org/10.1159/000500558>

Jeffreys, H. 1961. *Theory of probability*, Clarendon. Oxford.

Kalva, J.J., Sims, C.A., Puentes, L.A., Snyder, D.J., and Bartoshuk, L.M. 2014. Comparison of the hedonic general labeled magnitude scale with the hedonic 9-point scale. *Journal of Food Science*. 79:S238—S245.

Landis, B.N., Hummel, T., Hugentobler, M., Giger, R., and Lacroix, J. 2003. Ratings of overall olfactory function. *Chemical Senses*. 28:691–694.

Lechien, J.R., Cabaraux, P., Chiesa-Estomba, C.M., and Khalife, M. 2020a. Objective olfactory testing in patients presenting with sudden onset olfactory dysfunction as the first manifestation of confirmed covid-19 infection. Retrieved from Medrxiv.org. <https://doi.org/10.1101/2020.04.15.20066472>

Lechien, J.R., Chiesa-Estomba, C.M., De Siaty, D.R., Horoi, M., Le Bon, S.D., Rodriguez, A., Dequanter, D., Blecic, S., El Afia, F., Distinguin, L., et al. 2020b. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. <https://doi.org/10.1007/s00405-020-05965-1>

Lee, M.D., and Wagenmakers, E.-J. 2013. New York, NY: Cambridge University Press.

Lê, S., Josse, J., and Husson, F. 2008. FactoMineR: An r package for multivariate analysis. *Journal of Statistical Software*. 25:1–18.

Loetsch, J., and Hummel, T. 2006. The clinical significance of electrophysiological measures of olfactory function. *Behavioural Brain Research*. 170:78–83. <https://doi.org/10.1016/j.bbr.2006.02.013>

Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., et al. 2020. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurology*. <https://doi.org/10.1001/jamaneurol.2020.1127>

Marwick, B. 2019. rrttools: Creates a reproducible research compendium (R package version 0.1. 0)[Computer software manual]. <https://github.com/benmarwick/rrttools>

McDonald, S.T., Bolliet, D.A., and Hayes, J.E. 2016. *Chemesthesis: Chemical Touch in Food and Eating*. John Wiley & Sons. <https://doi.org/10.1002/9781118951620>

Menni, C., Valdes, A., Freydin, M.B., Ganesh, S., Moustafa, J.E.-S., Visconti, A., Hysi, P., Bowyer, R.C.E., Mangino, M., Falchi, M., et al. 2020. Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection. medRxiv. 2020.04.05.20048421. <https://doi.org/10.1101/2020.04.05.20048421>

Moein, S.T., Hashemian, S.M., Mansourafshar, B., Khorram-Tousi, A., Tabarsi, P., and Doty, R.L. 2020. Smell dysfunction: A biomarker for covid-19. In: International Forum of Allergy & Rhinology. Wiley Online Library. <https://doi.org/10.1002/alr.22587>

Morey, R.D., and Rouder, J.N. 2018. BayesFactor: Computation of Bayes Factors for Common Designs. <https://cran.r-project.org/package=BayesFactor>

Moshontz, H., Campbell, L., Ebersole, C.R., IJzerman, H., Urry, H.L., Forscher, P.S., Grahe, J.E., McCarthy, R.J., Musser, E.D., Antfolk, J., et al. 2018. The Psychological Science Accelerator: Advancing psychology through a distributed collaborative network. *Advances in Methods and Practices in Psychological Science*. 1:501–515.

Nordin, S., and Brämerson, A. 2008. Complaints of olfactory disorders: Epidemiology, assessment and clinical implications. *Current Opinion in Allergy and Clinical Immunology*. 8:10–15. <https://doi.org/10.1097/ACI.0b013e3282f3f473>

Oleszkiewicz, A., Kunkel, F., Larsson, M., and Hummel, T. 2020. Consequences of undetected olfactory loss for human chemosensory communication and well-being. *Philosophical Transactions of the Royal Society B*. 375:20190265.

Patel, Z.M. 2020. CORRESPONDANCE: Reflections and new developments within the COVID-19pandemic. *International Forum of Allergy & Rhinology*. alr.22582. <https://doi.org/10.1002/alr.22582>

Patil, I., and Powell, C. 2018. Ggstatsplot:“Ggplot2” based plots with statistical details. CRAN. Retrieved from <https://cran.r-project.org/web/packages/ggstatsplot> ....

Pellegrino, R., Cooper, K., Di Pizio, A., Bhutani, S., and Parma, V. 2020. Corona viruses and the chemical senses: Past, present, and future. *Chemical Senses*, in press

Pellegrino, R., Walliczek-Dworschak, U., Winter, G., Hull, D., and Hummel, T. 2017. Investigation of chemosensitivity during and after an acute cold. In: *International Forum of Allergy & Rhinology*. Wiley Online Library. pp. 185–191.

Reden, J., Maroldt, H., Fritz, A., Zahnert, T., and Hummel, T. 2007. A study on the prognostic significance of qualitative olfactory dysfunction. *European Archives of Oto-Rhino-Laryngology*. 264:139–144. <https://doi.org/10.1007/s00405-006-0157-0>

Ren, Y., Yang, L., Guo, Y., Xutao, M., Li, K., and Wei, Y. 2012. Intranasal trigeminal chemosensitivity in patients with postviral and post-traumatic olfactory dysfunction. *Acta Oto-Laryngologica*. 132:974–980.

Rombaux, P., Martinage, S., Huart, C., and Collet, S. 2009. Post-infectious olfactory loss: A cohort study and update. *Acta Oto-Rhino-Laryngologica Belgica*. 8:89.

Rozin, P. 1982. “Taste-smell confusions” and the duality of the olfactory sense. *Perception & Psychophysics*. 31:397–401. <https://doi.org/10.3758/BF03202667>

Rubin, D.I., and Daube, J.R. 1999. Subacute sensory neuropathy associated with Epstein-Barr virus. *Muscle and Nerve*. 22:1607–1610.

Schönbrodt, F.D., and Wagenmakers, E.-J. 2018. Bayes factor design analysis: Planning for compelling evidence. *Psychonomic Bulletin & Review*. 25:128–142.

Schönbrodt, F.D., Wagenmakers, E.-J., Zehetleitner, M., and Perugini, M. 2017. Sequential hypothesis testing with Bayes factors: Efficiently testing mean differences. *Psychological Methods*. 22:322.

Shepherd, G.M. 2006. Smell images and the flavour system in the human brain. *Nature*. 444:316–321. <https://doi.org/10.1038/nature05405>

Soler, Z.M., Patel, Z.M., Turner, J.H., and Holbrook, E.H. 2020. A primer on viral-associated olfactory loss in the era of COVID-19. In: *International Forum of Allergy & Rhinology*. Wiley Online Library.

Spence, C., Auvray, M., and Smith, B. 2014. Confusing Tastes with Flavours. *Perception and Its Modalities*. 247–274.

Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., Sampaziotis, F., et al. 2020. SARS-cov-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nature Medicine*. 1–7.

Suzuki, M., Saito, K., Min, W.-P., Vladau, C., Toida, K., Itoh, H., and Murakami, S. 2007. Identification of viruses in patients with postviral olfactory dysfunction. *The Laryngoscope*. 117:272–277. <https://doi.org/10.1097/01.mlg.0000249922.37381.1e>

Team R Core Development. 2013. R: a language and environment for statistical computing. Retrieved from <http://www.r-project.org/>

Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A.S., Mehra, M.R., Schuepbach, R.A., Ruschitzka, F., and Moch, H. 2020. Endothelial cell infection and endotheliitis in covid-19. *The Lancet*.

Veldhuizen, M., Parma, V., Reed, D, Liuzza, M.T. 2020. GCCR001 - Quantifying smell, taste and chemesthesis changes in covid19: A multi-national study. OSF. Retrieved from [osf.io/auhs8](https://osf.io/auhs8).

Venkatakrishnan, A., Puranik, A., Anand, A., Zemmour, D., Yao, X., Wu, X., Chilaka, R., Murakowski, D.K., Standish, K., Raghunathan, B., et al. 2020. Knowledge synthesis from 100 million biomedical documents augments the deep expression profiling of coronavirus receptors. *arXiv Preprint arXiv:200312773*.

Vetter, P., Vu, D.L., L'Huillier, A.G., Schibler, M., Kaiser, L., and Jacquerioz, F. 2020. Clinical features of covid-19. *Bmj*. m1470. <https://doi.org/10.1136/bmj.m1470>

Welge-Lüssen, A., Hummel, T., Stojan, T., and Wolfensberger, M. 2005. What is the correlation between ratings and measures of olfactory function in patients with olfactory loss? *American Journal of Rhinology*. 19:567–571. <https://doi.org/10.1177/194589240501900606>

Workman, A.D., Welling, D.B., Carter, B.S., Curry, W.T., Holbrook, E.H., Gray, S.T., Scangas, G.A., and Bleier, B.S. 2020. Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. *International Forum of Allergy & Rhinology*.

World Health Organization. 2020. Q&A on coronaviruses (COVID-19). Retrieved on May 1, 2020 from <https://www.who.int/news-room/q-a-detail/q-a-coronaviruses>

Yan, C.H., Faraji, F., Prajapati, D.P., Boone, C.E., and DeConde, A.S. 2020a. Association of chemosensory dysfunction and covid-19 in patients presenting with influenza-like symptoms. In: *International Forum of Allergy & Rhinology*. Wiley Online Library.

Yan, C.H., Faraji, F., Prajapati, D.P., Ostrander, B.T., and DeConde, A.S. 2020b. Self-reported olfactory loss associates with outpatient clinical course in Covid-19. International Forum of Allergy & Rhinology. <https://doi.org/10.1002/alr.22592>

Yu, H. 2017. Bootcluster: Bootstrapping estimates of clustering stability. CRAN. Retrieved from <https://cran.r-project.org/package=bootcluster>.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. 2020. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 382:727–733. <https://doi.org/10.1056/NEJMoa2001017>